UB Paderborn / Katalog / Suche / in CDI

Abstract 12680: Efficacy and Safety of Edoxaban Compared With Warfarin in Patients With Atrial Fibrillation and Heart Failure: Insights From Engage-AF TIMI 48

Circulation (New York, N.Y.), 2014-11, Vol.130 (suppl_2)

2014

Volltextzugriff (PDF)

Abstract 19119: Concomitant Use of Antiplatelet Therapy with Edoxaban or Warfarin in Patients with Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

Circulation (New York, N.Y.), 2014-11, Vol.130 (suppl_2)

2014

Volltextzugriff (PDF)

Adoptive Control of Injector for Polymer Electrolyte Membrane Fuel Cell Hydrogen Feeding System

2021 IEEE 4th International Electrical and Energy Conference (CIEEC), 2021, p.1-6

2021

Volltextzugriff (PDF)

An Analysis of Paediatric CD4 Counts for Acquired Immune Deficiency Syndrome Using Flexible Random Curves

Applied Statistics, 1996-01, Vol.45 (2), p.151-163

1996

Volltextzugriff (PDF)

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

The Lancet (British edition), 2015-06, Vol.385 (9984), p.2288-2295

2015

Volltextzugriff (PDF)

CARDIAC STRUCTURE AND FUNCTION AND CHADS2 RISK SCORE IN PATIENTS WITH ATRIAL FIBRILLATION: THE EFFECTS ANTICOAGULATION WITH FACTOR XA NEXT GENERATION IN AFTHROMBOLYSIS IN MYOCARDIAL INFARCTION 48 (ENGAGE AF -TIMI 48) ECHOCARDIOGRAPHIC STUDY

Journal of the American College of Cardiology, 2013-03, Vol.61 (10), p.E964-E964

2013

Volltextzugriff (PDF)

Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

Stroke (1970), 2014-08, Vol.45 (8), p.2372-2378

2014

Volltextzugriff (PDF)

Cerebrovascular Events in 21105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

Stroke (1970), 2014, Vol.45 (8), p.2372-2378

2014

Volltextzugriff (PDF)

Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery

Thrombosis and haemostasis, 2012-11, Vol.108 (5), p.887

2012

Volltextzugriff (PDF)

Characterization of pre- and post-failure displacements of the Huangnibazi landslide in Li County with multi-source satellite observations

Engineering geology, 2019-07, Vol.257, p.105140, Article 105140

2019

Volltextzugriff (PDF)

Chitinase-3 like-protein-1 promotes glioma progression via the NF-κB signaling pathway and tumor microenvironment reprogramming

Theranostics, 2022-01, Vol.12 (16), p.6989-7008

2022

Volltextzugriff (PDF)

Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial

International journal of cardiology, 2018-04, Vol.257, p.102-107

2018

Volltextzugriff (PDF)

Comparative Efficacy of Oral Extended-Release Hydromorphone and Immediate-Release Hydromorphone in Patients with Persistent Moderate to Severe Pain: Two Randomized Controlled Trials

Journal of pain and symptom management, 2005-06, Vol.29 (6), p.584-594

2005

Volltextzugriff (PDF)

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial

Journal of the American Heart Association, 2016-02, Vol.5 (2), p.n/a

2016

Volltextzugriff (PDF)

Correction to “The Discovery of 3,3′-Spiro[azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection”

ACS medicinal chemistry letters, 2018-04, Vol.9 (4), p.397-397

2018

Volltextzugriff (PDF)

Dendrite‐accelerated thermal runaway mechanisms of lithium metal pouch batteries

SusMat (Online), 2022-08, Vol.2 (4), p.435-444

2022

Volltextzugriff (PDF)

Discovery of 3,3′-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection

ACS medicinal chemistry letters, 2018-02, Vol.9 (2), p.94-97

2018

Volltextzugriff (PDF)

A Downscaling Framework for Urban Nighttime Light Based on Multifactor Geographically Neural Network Weighted Regression

IEEE transactions on geoscience and remote sensing, 2024, Vol.62, p.1-16

2024

Volltextzugriff (PDF)

DRUG-DRUG INTERACTION STUDIES OF CARDIOVASCULAR DRUGS (AMIODARONE, DIGOXIN, QUINIDINE, ATORVASTATIN AND VERAPAMIL) INVOLVING P-GLYCOPROTEIN (P-GP), AN EFFLUX TRANSPORTER, ON THE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF EDOXABAN, AN ORAL FACTOR XA INHIBITOR

Journal of the American College of Cardiology, 2011-04, Vol.57 (14), p.E1510-E1510

2011

Volltextzugriff (PDF)

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2013-10, Vol.13 (5), p.331-342

2013

Volltextzugriff (PDF)

Early Levels of CD4, Neopterin, and [beta]^sub 2^-Microglobulin Indicate Future Disease Progression

Journal of clinical immunology, 1997-01, Vol.17 (1), p.43

1997

Volltextzugriff (PDF)

Early levels of CD4, neopterin, and β2-Microglobulin indicate future disease progression

Journal of clinical immunology, 1997, Vol.17 (1), p.43-52

1997

Volltextzugriff (PDF)

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

British journal of clinical pharmacology, 2016-12, Vol.82 (6), p.1591-1600

2016

Volltextzugriff (PDF)

Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min

Clinical pharmacology in drug development, 2022-05, Vol.11 (5), p.666-674

2022

Volltextzugriff (PDF)

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

The New England journal of medicine, 2018-02, Vol.378 (7), p.615-624

2018

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Abstract 12680: Efficacy and Safety of Edoxaban Compared With Warfarin in Patients With Atrial Fibrillation and Heart Failure: Insights From Engage-AF TIMI 48

Abstract 19119: Concomitant Use of Antiplatelet Therapy with Edoxaban or Warfarin in Patients with Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

Adoptive Control of Injector for Polymer Electrolyte Membrane Fuel Cell Hydrogen Feeding System

An Analysis of Paediatric CD4 Counts for Acquired Immune Deficiency Syndrome Using Flexible Random Curves

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

CARDIAC STRUCTURE AND FUNCTION AND CHADS2 RISK SCORE IN PATIENTS WITH ATRIAL FIBRILLATION: THE EFFECTS ANTICOAGULATION WITH FACTOR XA NEXT GENERATION IN AFTHROMBOLYSIS IN MYOCARDIAL INFARCTION 48 (ENGAGE AF -TIMI 48) ECHOCARDIOGRAPHIC STUDY

Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

Cerebrovascular Events in 21105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery

Characterization of pre- and post-failure displacements of the Huangnibazi landslide in Li County with multi-source satellite observations

Chitinase-3 like-protein-1 promotes glioma progression via the NF-κB signaling pathway and tumor microenvironment reprogramming

Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial

Comparative Efficacy of Oral Extended-Release Hydromorphone and Immediate-Release Hydromorphone in Patients with Persistent Moderate to Severe Pain: Two Randomized Controlled Trials

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial

Correction to “The Discovery of 3,3′-Spiro[azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection”

Dendrite‐accelerated thermal runaway mechanisms of lithium metal pouch batteries

Discovery of 3,3′-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection

A Downscaling Framework for Urban Nighttime Light Based on Multifactor Geographically Neural Network Weighted Regression

DRUG-DRUG INTERACTION STUDIES OF CARDIOVASCULAR DRUGS (AMIODARONE, DIGOXIN, QUINIDINE, ATORVASTATIN AND VERAPAMIL) INVOLVING P-GLYCOPROTEIN (P-GP), AN EFFLUX TRANSPORTER, ON THE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF EDOXABAN, AN ORAL FACTOR XA INHIBITOR

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor

Early Levels of CD4, Neopterin, and [beta]^sub 2^-Microglobulin Indicate Future Disease Progression

Early levels of CD4, neopterin, and β2-Microglobulin indicate future disease progression

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

Suchergebnisse filtern